Loading...
AMEX: SER
Serina Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$27.40M
52w High
$7.92
52w Low
$1.22
P/E
-1.41
Volume
13.19M
Outstanding Shares
10.79M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -44.05%Revenue (TTM): -96.27%FCF (TTM): -32.08%
What changed
The stock fell 44.05% over the last year. Revenue declined 96.27% over the trailing twelve months. Operating margin moved from -362.46% to -20,141.38%. Free cash flow declined 32.08% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -20,141.38%. Revenue declined 96.27% — this read reverses if that trend stabilizes. Free cash flow fell 32.08% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
CEOSteven A. Ledger
SectorHealthcare
IndustryBiotechnology
Employees12
IPO dateJan 21, 2000
Valuation
Forward P/E—
EV/EBITDA-3.19
Enterprise value$33.46M
Stock splits
Mar 15, 20247:250
Profitability & growth
Revenue growth-100%
Gross margin56.9%▼353.67%vs FY2023
Operating margin-20,141.38%▼30576.36%vs FY2023
ROE-1,738.07%▼10552.70%vs FY2023
Analyst consensus
RatingBuy
Target price—
1
Buy
0
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 23, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
-$0.49
-$0.62
Q3FY25
ActualEst.
-$0.66
-$0.36
Q4FY25
ActualEst.
-$0.45
-$0.47
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
—
—
Q3FY25
ActualEst.
$130K
—
Q4FY25
ActualEst.
—
—
Q1FY26
Next Est.
—